Asceneuron (Switzerland)

Recent papers from Asceneuron (Switzerland)

1. Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy ParticipantsMovement Disorders · 2025
2. A framework for translating tauopathy therapeutics: Drug discovery to clinical trialsAlzheimer s & Dementia · 2024
3. Pathogenic Aβ production by heterozygous PSEN1 mutations is intrinsic to the mutant protein and not mediated by conformational hindrance of wild-type PSEN1Journal of Biological Chemistry · 2023
4. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein ProteinopathiesACS Chemical Neuroscience · 2022
5. Current directions in tau research: Highlights from Tau 2020Alzheimer s & Dementia · 2021
6. O1‐12‐05: Phase 1 Study in Healthy Volunteers of the O‐glcnacase Inhibitor Asn120290 as a Novel Therapy for Progressive Supranuclear Palsy and Related TauopathiesAlzheimer s & Dementia · 2018
7. O3‐04‐04: Pharmacological intervention with the novel o‐glcnacase inhibitor ASN‐561 reduces pathological tau in transgenic miceAlzheimer s & Dementia · 2015
8. Pharmacophore‐Based Design of Novel Oxadiazoles as Selective Sphingosine‐1‐phosphate (S1P) Receptor Agonists with in vivo EfficacyChemMedChem · 2015
9. O1‐10‐01: Preclinical Profiles of Drug Candidates Promoting O‐linked Glycosylation of Tau for the Treatment of Alzheimer's Disease and TauopathiesAlzheimer s & Dementia · 2014
10. Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathiesMolecular Neurodegeneration · 2013